A record year for new business

Cogstate Limited (ASX: CGS), the Melbourne-founded developer of digital cognitive assessments used in Alzheimer’s and central-nervous-system (CNS) drug trials, has delivered its strongest year of order intake on record. In a business update lodged with the ASX on 7 July 2026, the company reported net new sales contracts of US$89.0 million for the financial year ended 30 June 2026 — a 116 per cent increase on the US$41.3 million booked in FY25. Cogstate reports in US dollars, so every operating figure below is denominated in USD unless flagged otherwise.

The result was underpinned by a busy final quarter, with US$21.9 million of contracts executed in the three months to June alone. Because a large share of Cogstate’s revenue is earned by supplying cognitive-testing technology and services across the life of a multi-year clinical trial, the timing and scale of new bookings is the single most important leading indicator of future revenue. On that measure, FY26 marks a decisive rebound after a year in which the pace of contract signings had frustrated the market.

 

The pipeline that will shape FY27

Order intake matters most for what it locks in. Cogstate said its total contracted future revenue — work signed but not yet recognised — had expanded 32 per cent year-on-year to US$118.5 million heading into FY27. Of that, roughly US$48.3 million is expected to be recognised as revenue during FY27, with the balance of about US$70.2 million scheduled for FY28 and beyond, up around 20 per cent.

The composition is telling. Clinical-trials contracted revenue slated for FY27 rose 58 per cent to US$46.1 million, while the smaller healthcare segment’s contracted contribution was broadly flat at about US$2.3 million. That underscores a structural feature of the business: the clinical-trials franchise, which sells to pharmaceutical and biotechnology sponsors, does almost all of the heavy lifting, while the healthcare arm remains a modest adjacency. Investors assessing the stock should treat the contracted figure as visibility rather than certainty — revenue recognition depends on trial timing, patient recruitment and sponsor decisions that sit outside Cogstate’s control.

 

Reading the half-year that unsettled investors

The July update lands against the backdrop of a first half that tested sentiment. In results for the six months to 31 December 2025, released on 19 February 2026, Cogstate posted revenue of US$26.9 million, up 12 per cent. Clinical trials generated US$25.7 million (up 13 per cent) and healthcare US$1.2 million (down 2 per cent). Statutory net profit after tax rose 16 per cent to US$4.5 million, EBITDA improved 5 per cent to US$6.5 million, and earnings per share lifted to 2.65 US cents from 2.27 US cents.

Yet the reported gross margin compressed to roughly 52 per cent, below the low-60s the company had historically delivered, reflecting product mix and investment in delivery capacity. Management also flagged timing delays in converting and recognising work, and the shares sold off sharply in the days after the half-year release as investors reassessed the near-term revenue trajectory. It would be wrong to read the subsequent recovery as a mechanical response to any single announcement; shares have since firmed as the market weighed the improving order book, closing around A$2.73 (in Australian dollars) after the July update, for a market capitalisation of roughly A$465 million.

Notably, the board declined to declare an interim dividend for the half, consistent with its practice of assessing distributions on an annual basis. Cogstate ended December with US$34.1 million in cash and no debt, giving it latitude to fund growth internally.

 

Why the CNS tailwind matters

Cogstate’s fortunes are tied to the health of CNS drug development, and that backdrop has brightened. The regulatory clearance of anti-amyloid Alzheimer’s therapies lecanemab and donanemab has re-energised sponsor investment in cognitive-disease research, expanding the addressable pool of trials that require the standardised, digital cognitive endpoints Cogstate specialises in. The company’s active clinical-trials portfolio grew 34 per cent year-on-year to 133 studies at the half, and it has pushed beyond Alzheimer’s into psychiatry and rare diseases.

Distribution has been reshaped, too. Cogstate’s channel-partner program — anchored by its relationship with clinical-technology group Medidata — drove around 70 per cent of sales opportunities and 62 per cent of executed contracts in the half, leveraging partner sales forces to reach sponsors Cogstate might not access directly. Chief executive Brad O’Connor has argued the company’s competitive moat rests on proprietary data, pointing to “a unique dataset of thousands of recordings used to train bespoke AI models” that newer entrants cannot easily replicate.

 

Concentration and the questions still open

For all the momentum, the investment case carries identifiable risks. Contracted revenue includes around US$12.5 million tied to licences with Japanese pharmaceutical group Eisai, a reminder that a meaningful slice of forward revenue is concentrated in a small number of large relationships. The half also carried a US$0.5 million provision for doubtful debt linked to an unsuccessful US biotech study — a small figure, but a live illustration of the customer-credit and trial-attrition risks inherent in selling to early-stage sponsors.

The gap between booked contracts and recognised revenue also demands patience. A record US$89 million of FY26 signings will convert to reported sales only gradually, and the pace of that conversion — alongside gross-margin recovery — will determine whether the operating leverage investors expect actually materialises.

 

What to watch in August

Cogstate has said it will detail its full FY26 statutory results and outline FY27 priorities — including growth initiatives, technology investment and capital allocation — at an investor briefing in August. Those numbers had not been released as at the 29 July 2026 cut-off for this article, so the July update is best read as a leading indicator rather than a final scorecard. Key watch-points are whether second-half revenue recognition accelerated in line with the order book, whether gross margins began to recover, and how the board intends to deploy its debt-free balance sheet.

This article is provided for information only and does not constitute financial advice or a recommendation to buy, hold or sell any security.